WVEWave Life Sciences Ltd.
Price
-50%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, the market undecided.
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Wave Life Sciences Ltd. (WVE) reported revenue of $2.3M in Q2 2026 (quarter ended Jun 30, 2026), down 74% from the same quarter a year earlier. That came with net loss of $69M. For the full year FY2025, revenue was $43M (−61% year on year) and net income −$204M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 18, 2026The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
- Apr 28, 2026Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.